Vertex Pharmaceuticals, Inc.

Neurocrine Biosciences, Inc.

Crinetics Pharmaceuticals, Inc.

Joseph Pontillo

Dennis James Hurley

Ronald Marcellus Knegtel

Sara Sabina Hadida Ruah

Steven John Durrant

Joanne Louise Pinder

Dean P Stamos

Timothy Donald Neubert

David Matthew Shaw

Nadia M Ahmad

Stephen Andrew Thomson

Anisa Nizarali Virani

Robert Pullin

Lidio Marx Carvalho Meireles

Yvonne Schmidt

Sarah Skerratt

Ewa Iwona Chudyk

Bhairavi Galan

Christopher Wray

Gorka Etxebarria Jardi

Elizabeth Mary Beck

Mark Thomas Miller

Sara Sabina Hadida-Ruah

Vijayalaksmi Arumugam

Peter Diederik Jan Grootenhuis

Bryan A Frieman

Nicole Hilgraf

Dongpei Wu

Edward Adam Kallel

Jinglan Zhou

Brian Richard Bear

Jason McCartney

Corey Don Anderson

Hayley Marie Binch

Michael Edward O'Donnell

Warren Stanfield Wade

Pramod Virupax Joshi

Zhiqiang Guo

Alina Silina

Urvi Jagdishbhai Sheth

Michael P Deninno

Lev Tyler Dewey Fanning

Kiri North

James Dodd

Jian Zhao

Martin W Rowbottom

Chen Chen

Mi Chen

Brian Dyck

Junko Tamiya

Johnny Uy

Wendy Eccles

Yunfei Zhu

Troy Vickers

Shimiao Wang

James Philip Johnson

Mehdi Numa

Val S Goodfellow

Yinghong Gao

Sarah Clough

Mehrak Kiankarimi

Mingzhu Zhang

Mehdi Michael Djamel Numa

Jennings Franklin Worley, Iii

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Substituted tetrahydrofurans as modulators of sodium channels

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Nonpeptide somatostatin type 5 receptor agonists and uses thereof

The invention relates to benzoxazines useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Benzoxazines as modulators of ion channels

The invention relates to morpholine spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Morpholine-spirocyclic piperidine amides as modulators of ion channels

The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels

Monoamine re-uptake inhibitors and more specifically serotonin and noradrenaline re-uptake inhibitors are disclosed that have utility in the treatment of disorders of the central or peripheral nervous system in both men and women. The compounds of this invention have the structure: wherein R, R, R, R, R, R, m, n, W, X, Y, and Z are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts, esters and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting monoamine re-uptake in a subject in need thereof.

Monoamine re-uptake inhibitors and methods relating thereto

Melanin-concentrating hormone (MCH) receptor antagonists are disclosed having utility for the treatment of MCH receptor-based disorders such as obesity. The compounds of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, R, R, R, R, R, and Rare as defined herein. Pharmaceutical compositions containing a compound of this invention, as well as methods relating to the use thereof, are also disclosed.

Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:wherein R, R, R, R, R, R, and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Growing community of inventors

San Diego, CA, United States of America

Joseph Pontillo